Decoding MS: Can a Common Virus Be the Missing Piece?
"New research unveils how herpesviruses might trigger multiple sclerosis, paving the way for future prevention strategies."
Multiple sclerosis (MS), a debilitating autoimmune disease, has long puzzled scientists. While genetic predisposition plays a role, environmental factors, particularly viral infections, are increasingly suspected as triggers. Among these, human herpesviruses (HHVs), such as Epstein-Barr virus (EBV) and human herpesvirus 6 (HHV-6), have emerged as prime suspects.
However, the challenge lies in the timing. HHV infections are incredibly common, often occurring in early childhood, while MS typically manifests in adulthood. This time gap makes it difficult to establish a direct causal link. Now, a new study using nonhuman primates offers compelling evidence of how HHV-6 might accelerate the development of an MS-like disease.
This article delves into the groundbreaking research that demonstrates how asymptomatic HHV-6 infection can act as a trigger, accelerating neuroinflammation and mimicking the progression of MS in a nonhuman primate model. We'll explore the study's findings, their implications for understanding MS, and the potential for future preventative strategies.
Evidence and Uncertainty Around Herpesviruses
Multiple sclerosis (MS) is described as a multifactorial disease of unknown origin, with Epstein–Barr virus (EBV) and human herpesvirus 6 (HHV-6) having particularly strong associations; both are typically acquired in childhood, often decades before MS presents. A 2023 review notes that findings on herpesvirus DNA detection in people with MS are controversial: some studies report increased risk alongside more frequent detection, while others report opposite results. Separately, evidence from samples collected before symptoms found HHV-6A seropositivity significantly associated with the MS prodrome. These findings support continued investigation, but do not settle the viruses’ roles in MS.
Longstanding Viral Hypotheses
Herpesviruses have had a longstanding clinical association with multiple sclerosis, according to a 2021 review. It names Epstein–Barr virus, HHV-6, HHV-1, varicella-zoster virus (VZV), and human endogenous retroviruses among the viruses considered in this connection. The review describes MS as an autoimmune disease of the nervous system in which the myelin sheath deteriorates, and identifies molecular mimicry as a prominent proposed way viruses may manipulate immune responses. These are historical lines of inquiry, not proof that any one virus causes MS.
The Herpesvirus-MS Connection: What the Study Revealed
Researchers at the National Institutes of Health investigated the impact of HHV-6 on experimental autoimmune encephalomyelitis (EAE), an animal model for MS, using common marmosets. Marmosets are susceptible to HHV-6 infection and exhibit EAE with similarities to MS in humans, making them an ideal model.
- Asymptomatic Infection: Marmosets inoculated with HHV-6 remained asymptomatic, mirroring the typical course of early HHV-6 infection in humans.
- Accelerated EAE: Despite the lack of symptoms, HHV-6-infected marmosets experienced a significantly faster onset and more severe progression of EAE compared to control animals.
- Immune Response: An expansion of a pro-inflammatory CD8 T cell subset correlated with survival rates in the virus/EAE marmosets, hinting at a possible viral antigen-driven immune response.
- Viral Antigen Localization: HHV-6 viral antigen was markedly elevated and concentrated within brain lesions of virus/EAE marmosets, similar to what has been observed in MS brain lesions.
Marmoset Models and Antiviral Research
Recent work described screening more than 450 common marmosets from five U.S. biomedical research colonies for Callitrichine herpesvirus 3 (CalHV-3) using droplet digital PCR. A separate study tested brincidofovir (BCV) against Epstein–Barr virus and related gammaherpesvirus in human and nonhuman-primate cells, including cells from marmosets naturally infected with CalHV-3. The marmoset is also used to investigate MS: infection with HHV-6 can accelerate progression of experimental autoimmune encephalomyelitis, an MS-like disease, in this model. These findings concern model systems and antiviral activity in cells; they do not establish a treatment for MS.
A Model-Specific Immune Finding
In a nonhuman-primate model of MS, researchers reported a significant correlation between effector/memory CD8 T-cell levels and time after experimental autoimmune encephalomyelitis (EAE) induction in marmosets given both virus and EAE. They did not find this correlation in the control marmosets given EAE without the virus. This result is a model-specific immune observation and, on its own, does not establish that herpesvirus infection causes MS in people.
Different Evidence for HHV-6 and EBV
A 2022 review set out to update evidence on the relationship between HHV-6 infection and MS and assess the quality of the available studies. Another 2022 paper describes the role of HHV-6A or HHV-6B in MS pathogenesis as controversial, noting challenges that include possible effects before clinical symptoms and difficulty detecting active infection or separating serological responses. A 2026 report says a new study confirms that EBV infection increases MS risk and that common herpesviruses have differing roles in the disease. Together, these sources point to distinct and uneven evidence across viruses, rather than a single established role for all herpesviruses.
Implications and Future Directions: What This Means for MS
This research provides compelling evidence for the role of HHV-6 as a potential trigger for MS. It suggests that early exposure to the virus, even without causing noticeable symptoms, can alter the immune system and increase the risk of developing the disease later on.
Clarifying HHV-6A and HHV-6B
A review reports that HHV-6A and HHV-6B are neurotropic and can establish lifelong latency in cells of the central nervous system, with the potential to reactivate later. It links HHV-6A with increased MS risk, while indicating HHV-6B may be involved in epilepsy pathogenesis. A 2023 news report describes a study suggesting HHV-6A infection is linked with more nerve damage in the years before MS onset. These reported associations make it important for future research to distinguish the two variants and examine their timing and effects.
The study's findings open new avenues for MS prevention and treatment. Future research could focus on:
<ul> <li><b>Antiviral Therapies:</b> Investigating whether antiviral medications can prevent or delay the onset of MS in individuals with HHV-6 infection.</li> <li><b>Vaccine Development:</b> Developing a vaccine against HHV-6 to reduce the risk of infection and subsequent MS development.</li> <li><b>Immune Modulation:</b> Exploring strategies to modulate the immune system in individuals with HHV-6 infection to prevent the development of autoimmunity.</li> </ul> <br>By further exploring the link between herpesviruses and MS, we can pave the way for innovative strategies to prevent and treat this debilitating disease, offering hope for millions affected worldwide.